Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry studyDavid J. Pinato, Enrico Caliman, Daniela Ferrante et al.|The Lancet Oncology|2022Cited by 80
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registryLaia Garrigós, Maria Belen Delany, Sònia Pernas et al.|Therapeutic Advances in Medical Oncology|2021Cited by 7
155TiP A randomised phase II trial of neoadjuvant multi-agent chemotherapy (CHT) OR patritumab deruxtecan (HER3-DXd; U3-1402) +/- endocrine therapy (ET) for high-risk hormone receptor-positive (HR+/HER2-) early breast cancer (EBC): SOLTI-2103 VALENTINE trialMafalda Oliveira, Aleix Prat, Tomás Pascual et al.|ESMO Open|2023Cited by 6
Abstract LB1-06: Primary results of SOLTI VALENTINE: neoadjuvant randomized phase II trial of HER3-DXd alone or in combination with letrozole for high-risk hormone receptor positive (HR+)/HER2-negative (neg) early breast cancer (EBC)Mafalda Oliveira, Aleix Prat, Tomás Pascual et al.|Clinical Cancer Research|2025Cited by 3
195P Health-related quality of life outcomes in SOLTI VALENTINE: A trial of neoadjuvant HER3-DXd +/- letrozole for high-risk hormone receptor positive/HER2-negative early breast cancerGuillermo Villacampa, Ana Muntañola Prat, Mikele Praia de Oliveira et al.|ESMO Open|2025Cited by 1